NASDAQ · JNJ
Healthcare · Drug Manufacturers - General
$278.43
Down-$1.87 (-0.67%)
Updated Sep 4, 2026, 4:01 PM
SID Score
7.8/10
Composite research score
Smart Money
57/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
JNJ closed at $278.43 after 21 trading sessions, up 8.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $277.32 | $278.89 | $273.155 | $278.43 | 5.94M |
| Sep 2, 2026 | $274.74 | $281.07 | $273.53 | $275.21 | 7.91M |
| Sep 1, 2026 | $270.83 | $271.91 | $267.02 | $271.19 | 6.04M |
| Aug 31, 2026 | $267.125 | $267.77 | $265.17 | $265.85 | 7.9M |
| Aug 28, 2026 | $265.78 | $268.38 | $264.27 | $268.04 | 5.77M |
| Aug 27, 2026 | $268.45 | $268.45 | $263.83 | $265.77 | 7.31M |
| Aug 26, 2026 | $271.97 | $272.905 | $269.55 | $270.00 | 7.22M |
| Aug 25, 2026 | $271.00 | $273.8021 | $270.175 | $273.14 | 4.69M |
| Aug 24, 2026 | $269.74 | $273.98 | $268.57 | $273.04 | 5.44M |
| Aug 21, 2026 | $267.83 | $272.655 | $267.00 | $270.24 | 6.19M |
| Aug 20, 2026 | $273.40 | $273.40 | $267.37 | $267.37 | 6.48M |
| Aug 19, 2026 | $272.995 | $276.47 | $270.56 | $273.41 | 7.73M |
| Aug 18, 2026 | $267.67 | $271.73 | $266.33 | $271.11 | 7.84M |
| Aug 17, 2026 | $258.87 | $264.2775 | $258.01 | $262.37 | 5.52M |
| Aug 14, 2026 | $260.65 | $261.71 | $259.16 | $260.35 | 5M |
| Aug 13, 2026 | $261.725 | $262.62 | $259.6475 | $262.08 | 4.85M |
| Aug 12, 2026 | $256.00 | $261.41 | $255.255 | $260.86 | 4.63M |
| Aug 11, 2026 | $261.23 | $264.15 | $258.36 | $259.80 | 5.95M |
| Aug 10, 2026 | $259.06 | $262.00 | $258.55 | $261.81 | 8.99M |
| Aug 7, 2026 | $255.89 | $259.60 | $255.12 | $259.24 | 6.53M |
| Aug 6, 2026 | $261.71 | $262.11 | $255.28 | $256.98 | 6.93M |
The latest Smart Investors Daily articles mentioning JNJ.
JNJ research
Company profile and research snapshot.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | UBS | Buy | — |
| Aug 6, 2026 | Guggenheim | Buy | — |
| Aug 3, 2026 | Wells Fargo | Overweight | — |
| Jul 17, 2026 | Guggenheim | Buy | — |
| Jul 16, 2026 | Wells Fargo | Overweight | — |
Generated Sep 4, 2026, 3:15 PM
Johnson & Johnson shares declined 0.91% today, despite receiving a significant price target boost from UBS Securities that lifted its rating to $320. The modest pullback appears to reflect profit-taking after the analyst upgrade, while the broader healthcare sector showed strength with multiple stocks advancing during afternoon trading sessions.
Bottom line: JNJ's modest decline today masks an otherwise constructive fundamental picture, evidenced by UBS's upgraded price target and confidence in the company's pipeline. While litigation overhang and growth headwinds warrant monitoring, the analyst validation and sector momentum suggest the risk-reward may be becoming more attractive for patient investors with a multi-year horizon.
Yahoo · Sep 4, 2026
Sixty-four straight years of dividend growth sounds like a headline, but the real story is what keeps that streak alive even as one of JNJ's biggest drugs faces a brutal competitive hit.
Yahoo · Sep 4, 2026
Johnson & Johnson (JNJ) is back in the spotlight after a Louisiana jury found the company liable in a talc related mesothelioma case, adding a fresh layer to its ongoing litigation risk. Against this backdrop, Johnson & Johnson’s recent 7 day share price return of 4.76% and 30 day share price return of 9.22% indicate that momentum has been building ahead of the Louisiana verdict and the latest FDA approval, while the 1 year total shareholder return of 59.27% and 5 year total shareholder...
Yahoo · Sep 2, 2026
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Yahoo · Sep 2, 2026
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State
Interpretive context generated from the platform’s current data sources.
Johnson & Johnson shares traded at $278.43, reflecting a modest intraday decline of 0.38% per SID market data. Over the trailing twelve months, JNJ has appreciated 36.29%, significantly outperforming its typically defensive profile, with a beta of just 0.349 indicating substantially lower volatility than the broader market. On a shorter-term basis, the stock gained 7.96% over the past month and 23.28% over three months, demonstrating sustained upward momentum. Technical indicators confirm this trend, with shares trading well above both the 50-day moving average of $260.41 and the 200-day moving average of $241.16, according to Massive/Polygon data. The 14-day RSI reads 63.7, approaching but not yet reaching overbought territory. Average daily trading volume stands at approximately 8.82 million shares, supporting orderly price discovery. The company's market capitalization currently sits at approximately $505.78 billion, reinforcing its mega-cap healthcare status.
Johnson & Johnson currently trades at a price-to-earnings ratio of 20.30, positioning it within a moderate valuation range for the healthcare sector, per SID market data. The PEG ratio of 1.91 suggests the stock is priced slightly above its earnings growth trajectory, as values above 1.0 generally indicate a premium relative to expected growth rates. The price-to-book ratio stands at 6.43, reflecting the market's recognition of Johnson & Johnson's substantial intangible assets, brand equity, and pharmaceutical pipeline value, according to SEC filings. The company maintains a dividend yield of approximately 2.45%, consistent with its long-standing status as a Dividend Aristocrat. Within the healthcare sector, these metrics indicate a valuation that accounts for Johnson & Johnson's diversified revenue streams across pharmaceuticals, MedTech, and consumer health segments following the Kenvue separation. The current valuation framework reflects a balance between defensive stability and growth expectations embedded in the share price.
Johnson & Johnson's composite smart money score registers at 57 out of 100, signaling a neutral positioning among sophisticated market participants, per SID market data. Institutional ownership confidence is rated at a maximum 25 out of 25, indicating robust conviction from large asset managers and mutual fund complexes. In contrast, insider activity scores a more modest 8.6 out of 25, with SEC Form 4 filings revealing 19 insider transactions over the past 90 days, comprising 8 purchases and 11 sales. This net selling pattern among corporate insiders warrants monitoring, though it may reflect routine compensation-related dispositions. Dark pool activity scores 9.4 out of 25, suggesting limited off-exchange accumulation by institutional buyers. Congressional trading interest is moderate at 13.8 out of 25, according to publicly disclosed congressional trade filings. The divergence between strong institutional confidence and weaker insider sentiment creates a mixed signal landscape, with the overall neutral composite reflecting these offsetting factors across the four tracked smart money dimensions.
Johnson & Johnson has demonstrated a consistent pattern of meeting or exceeding earnings expectations across recent quarters, according to company earnings reports. In the most recent quarter reported in July 2026, the company posted earnings per share of $2.90 versus analyst estimates of $2.85, delivering a positive surprise of $0.05. The prior quarter saw EPS of $2.70 against consensus of $2.67, another beat of $0.03. The January 2026 quarter represented the sole miss in the trailing four-quarter period, with actual EPS of $2.46 falling just $0.01 below the $2.47 estimate. The September 2025 quarter produced EPS of $2.80 versus the $2.78 estimate, per analyst estimates. Across these four quarters, Johnson & Johnson achieved a cumulative positive earnings surprise, with three of four quarters exceeding consensus. The sequential EPS trajectory from $2.46 to $2.90 reflects meaningful quarter-over-quarter earnings growth, underscoring operational execution across the company's business segments.
Wall Street consensus on Johnson & Johnson remains firmly constructive, with recent analyst actions uniformly reaffirming bullish stances, per SID consensus data. UBS reiterated its Buy rating on September 2, 2026, maintaining its positive outlook on the company's growth trajectory. Guggenheim also maintained its Buy recommendation in both its August 6, 2026 update and a prior July 17, 2026 note, according to Wall Street analyst reports. Wells Fargo has twice reaffirmed its Overweight rating, on August 3 and July 16 of 2026, reflecting continued confidence in the company's fundamental positioning. Notably, all five most recent analyst actions represent rating reiterations rather than upgrades or downgrades, suggesting a stable and entrenched bullish consensus. No recent downgrades or initiations at Hold or Sell have appeared in the available coverage. This unanimity among major investment banks — UBS, Guggenheim, and Wells Fargo — signals broad institutional agreement on the company's favorable risk-reward profile in the current healthcare landscape.
The latest Smart Investors Daily articles mentioning JNJ.
